Treatment of chondrodysplasia

Abstract

A pharmaceutical composition for treating chondrodystrophia and containing 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d] pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof. A therapeutic method using said pharmaceutical composition.

Description

[Technical Field]

[0001] [CROSS-REFERENCE TO RELATED APPLICATIONS] This application claims priority based on Japanese Patent Application No. 2020-014260, filed on January 31, 2020, the entire disclosure of which is incorporated herein by reference. The present invention relates to the treatment of chondrodysplasia (achondroplasia, hypochondroplasia, thanatophoric dysplasia) using FGFR inhibitors. [Background technology]

[0002] Fibroblast growth factors (FGFs) are expressed in a wide range of tissues and are one of the growth factors that regulate cell proliferation and differentiation. The physiological activity of FGFs is mediated by specific cell surface receptors, called fibroblast growth factor receptors (FGFRs). FGFRs belong to the receptor-type protein tyrosine kinase family and consist of an extracellular ligand-binding domain, a single transmembrane domain, and an intracellular tyrosine kinase domain. Four types of FGFRs have been identified to date (FGFR1, FGFR2, FGFR3, and FGFR4). FGFRs form dimers upon FGF binding and are activated by phosphorylation. Receptor activation induces the recruitment and activation of specific downstream signaling molecules, resulting in physiological functions.

[0003] Abnormalities in FGF / FGFR signaling have been reported to be associated with diseases related to abnormal chondrocyte differentiation in humans. Abnormal activation of FGF / FGFR signaling in diseases related to abnormal chondrocyte differentiation in humans is believed to be caused by genetic mutations in FGFR (Non-Patent Documents 1 and 2).

[0004] Point mutations such as G380R, N540K, and K650E in FGFR3 have been reported in achondroplasia, suggesting the possibility that such genetic mutations may be the cause of achondroplasia (Non-Patent Documents 3, 4, and 5). It has also been reported that the FGFR inhibitor NVP-BGJ398 has a therapeutic effect in a mouse model of achondroplasia caused by FGFR3Y367C, an activating mutation outside the kinase domain (Non-Patent Document 6). It has also been reported that NVP-BGJ398 exhibits a kinase inhibitory effect against the FGFR3G380R mutation at 50 nM. However, no therapeutic effect has been reported in a mouse model of achondroplasia caused by FGFR3G380R.

[0005] Disubstituted benzenealkynyl compounds having FGFR inhibitory effects have been reported (Patent Document 1), and it has also been reported that these compounds are effective against cancers with specific FGFR2 mutations (Patent Document 2), and that intermittent administration may be useful as an administration schedule (Patent Document 3). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] International Publication WO2013 / 108809 Brochure [Patent Document 2] International Publication WO2015 / 008844 Brochure [Patent Document 3] International Publication WO2015 / 008839 Brochure [Non-patent literature]

[0007] [Non-Patent Document 1] Dev Dyn. 2017 Apr;246(4):291-309. [Non-patent document 2] Am J Hum Genet. 2000 Dec;67(6):1411-21. [Non-patent document 3] Nature. 1994 Sep 15;371(6494):252-4. [Non-patent document 4] Nat Genet. 1995 Jul;10(3):357-9. [Non-patent document 5] Am J Med Genet. 1996 May 3;63(1):148-54. [Non-patent document 6] J Clin Invest. 2016 126(5):1871-1884 Summary of the Invention [Problem to be solved by the invention]

[0008] An objective of the present invention is to provide a novel pharmaceutical composition for treating chondrodysplasia and a treatment method using the pharmaceutical composition. [Means for solving the problem]

[0009] As a result of extensive research to solve the above-mentioned problems, the inventors of the present invention have found that 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one (Futibatinib) or a pharmaceutically acceptable salt thereof inhibits the phosphorylation of mutated FGFR3 and has excellent bone lengthening effects in chondrodysplasia.

[0010] That is, the present invention includes the following [1] to

[11] .

[0011] [1] A pharmaceutical composition for treating chondrodysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof.

[0012] [2] The pharmaceutical composition according to [1], wherein the chondrodysplasia is achondroplasia, hypochondroplasia, or thanatophoric dysplasia.

[0013] [3] The pharmaceutical composition according to [1] or [2], wherein the chondrogenic dysplasia is achondroplasia.

[0014] [4] The pharmaceutical composition according to any one of [1] to [3], wherein the chondrodysplasia is chondrodysplasia with an FGFR3 mutation.

[0015] [5] The pharmaceutical composition according to [4], wherein the FGFR3 mutation is a mutation of arginine at position 248, glycine at position 380, asparagine at position 540, or lysine at position 650 of FGFR3.

[0016] [6] The pharmaceutical composition according to [4], wherein the chondrodysplasia with an FGFR3 mutation is achondroplasia with an FGFR3 mutation.

[0017] [7] The pharmaceutical composition described in [6], wherein the achondroplasia is achondroplasia with an FGFR3 mutation in which glycine at position 380 of FGFR3 is mutated to arginine.

[0018] [8] The pharmaceutical composition according to [4], wherein the chondrodysplasia with an FGFR3 mutation is hypochondroplasia with an FGFR3 mutation.

[0019] [9] The pharmaceutical composition according to [8], wherein the hypochondroplasia is hypochondroplasia with an FGFR3 mutation in which asparagine at position 540 of FGFR3 is mutated to lysine.

[0020]

[10] The pharmaceutical composition according to [4], wherein the chondrodysplasia with an FGFR3 mutation is thanatophoric dysplasia with an FGFR3 mutation.

[0021]

[11] The pharmaceutical composition described in

[10] , wherein the thanatophoric dysplasia is thanatophoric dysplasia having an FGFR3 mutation in which arginine at position 248 of FGFR3 is mutated to cysteine, or an FGFR3 mutation in which lysine at position 650 is mutated to glutamic acid.

[0022] The present invention also relates to the following aspects: A therapeutic agent for chondrodysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof. 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof for use in the treatment of chondrodysplasia. Use of 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof for the treatment of chondrodysplasia. Use of 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating chondrodysplasia. A method for treating chondrodysplasia, comprising the step of administering an effective amount of 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof to a patient suffering from chondrodysplasia. A commercial package comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof as an active ingredient together with instructions for its use to treat chondrodysplasia in a subject. [Effects of the Invention]

[0023] According to the present invention, it is possible to provide a treatment for chondrodysplasia that has an excellent bone lengthening effect. [Brief explanation of the drawings]

[0024] [Figure 1] The graph shows the results of femur length measurements. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH vehicle-administered mice; ACH 0.1 mg / kg: ACH 0.1 mg / kg administered group; ACH 1 mg / kg: ACH 1 mg / kg administered group; ACH 3 mg / kg: ACH 3 mg / kg administered group. [Figure 2] The graph shows the results of measuring tibia length. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH mouse vehicle-administered group; ACH 0.1 mg / kg: ACH mouse 0.1 mg / kg administration group; ACH 1 mg / kg: ACH mouse 1 mg / kg administration group; ACH 3 mg / kg: ACH mouse 3 mg / kg administration group. [Figure 3] The graph shows the results of ulna length measurements. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH vehicle-administered mice; ACH 0.1 mg / kg: ACH 0.1 mg / kg administered group; ACH 1 mg / kg: ACH 1 mg / kg administered group; ACH 3 mg / kg: ACH 3 mg / kg administered group. [Figure 4]This figure shows the results of measuring the thickness of femoral growth cartilage plates. The vertical axis represents growth cartilage plate thickness (μm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH mouse vehicle-administered group; ACH 0.1 mg / kg: ACH mouse 0.1 mg / kg administration group; ACH 1 mg / kg: ACH mouse 1 mg / kg administration group; ACH 3 mg / kg: ACH mouse 3 mg / kg administration group. [Figure 5] This figure shows the results of measuring the thickness of tibial growth cartilage plates. The vertical axis represents growth cartilage plate thickness (μm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH mouse vehicle-administered group; ACH 0.1 mg / kg: ACH mouse 0.1 mg / kg administration group; ACH 1 mg / kg: ACH mouse 1 mg / kg administration group; ACH 3 mg / kg: ACH mouse 3 mg / kg administration group. [Figure 6] The graph shows the results of femur length measurements. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH mouse vehicle-administered group; ACH 1 mg / kg: ACH mouse 1 mg / kg administration group; ACH 3 mg / kg: ACH mouse 3 mg / kg administration group; ACH 10 mg / kg: ACH mouse 10 mg / kg administration group. [Figure 7] The graph shows the results of measuring tibia length. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH mouse vehicle-administered group; ACH 1 mg / kg: ACH mouse 1 mg / kg administration group; ACH 3 mg / kg: ACH mouse 3 mg / kg administration group; ACH 10 mg / kg: ACH mouse 10 mg / kg administration group. [Figure 8] The graph shows the results of ulna length measurements. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH vehicle-administered mice; ACH 1 mg / kg: ACH 1 mg / kg administered group; ACH 3 mg / kg: ACH 3 mg / kg administered group; ACH 10 mg / kg: ACH 10 mg / kg administered group. [Figure 9]The graph shows the results of femur length measurements. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH vehicle-administered mice; ACH 1 mg / kg: ACH 1 mg / kg administered group; ACH 3 mg / kg: ACH 3 mg / kg administered group; ACH 6 mg / kg: ACH 6 mg / kg administered group. [Figure 10] The graph shows the results of measuring tibia length. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH vehicle-administered mice; ACH 1 mg / kg: ACH 1 mg / kg administered group; ACH 3 mg / kg: ACH 3 mg / kg administered group; ACH 6 mg / kg: ACH 6 mg / kg administered group. [Figure 11] The graph shows the results of ulna length measurements. The vertical axis represents bone length (mm). The horizontal axis represents the following: WT: wild-type mice; ACH vehicle: ACH vehicle-administered mice; ACH 1 mg / kg: ACH 1 mg / kg administered group; ACH 3 mg / kg: ACH 3 mg / kg administered group; ACH 6 mg / kg: ACH 6 mg / kg administered group. [Figure 12] The results of the efficacy evaluation (safranin staining) using glycosaminoglycan as an indicator using iPS cells derived from patients with thanatophoric dysplasia type 1 (TD1) and achondroplasia chondroplasia (ACH) are shown. Vehicle: Vehicle (=0.1% DMSO) administration group, Compound 1 1 nM: 1 nM Compound 1 administration group. [Figure 13] The results of a drug efficacy evaluation using iPS cells derived from patients with thanatophoric dysplasia type 1 (TD1) and achondroplasia chondroplasia (ACH) were shown, with COL2A and ACAN mRNA expression as indicators. Measurements were performed using a Step One Plus Real-Time PCR System (Applied Biosystems). The vertical axis shows the ΔCt value using the GAPDH gene as an internal standard. The horizontal axis shows the following: Vehicle: vehicle (=0.1% DMSO) administration group, Compound 1: 1 nM Compound 1 administration group. DETAILED DESCRIPTION OF THE INVENTION

[0025] The present invention relates to a therapeutic agent for chondrodysplasia containing 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for treating chondrodysplasia containing 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof as an active ingredient, and a method of treatment using the pharmaceutical composition.

[0026] 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one (sometimes referred to as "Compound 1" in this specification) is a disubstituted benzenealkynyl compound having the following structure, and can be synthesized, for example, based on the production method described in International Publication No. WO2013 / 108809, although this is not particularly limited.

[0027] [ka]

[0028] In the present invention, Compound 1 can be used as it is or in the form of a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts of Compound 1 include, but are not limited to, addition salts with inorganic acids such as hydrochloric acid and sulfuric acid, and organic acids such as acetic acid, citric acid, tartaric acid, and maleic acid, salts with alkali metals such as potassium and sodium, salts with alkaline earth metals such as calcium and magnesium, and salts with organic bases such as ammonium salts, ethylamine salts, and arginine salts.

[0029] In the present invention, "FGFR3" includes FGFR3 from humans or non-human mammals, and preferably human FGFR3. The NCBI Gene ID for human FGFR3 is 2261. FGFR3 proteins also include isoforms, which are splicing variants, and examples of FGFR3 derived from humans include polypeptides consisting of the amino acid sequence (SEQ ID NO: 1) shown in NCBI Reference Sequence: NP_000133.

[0030] In the present invention, "FGFR3 mutation" is not particularly limited as long as it is an FGFR3 protein having an amino acid mutation that causes chondrodysplasia or an FGFR3 gene encoding said amino acid, but preferably refers to an FGFR3 protein having an amino acid sequence represented by SEQ ID NO: 1 in which at least one amino acid selected from the group consisting of arginine at position 248, glycine at position 380, asparagine at position 540, and lysine at position 650 is mutated, or an FGFR3 gene encoding said amino acid sequence in the case of an FGFR3 protein whose wild-type amino acid sequence differs from that of SEQ ID NO: 1, in which at least one amino acid at a position corresponding to the position in SEQ ID NO: 1 is mutated; more preferably refers to an FGFR3 protein having an amino acid sequence represented by SEQ ID NO: 1 in which at least one amino acid selected from the group consisting of arginine at position 248, glycine at position 380, and lysine at position 650 is mutated, or an FGFR3 gene encoding said amino acid sequence in the case of an FGFR3 protein whose wild-type amino acid sequence differs from that of SEQ ID NO: 1, in which at least one amino acid at a position corresponding to the position in SEQ ID NO: 1 is mutated; The present invention relates to an FGFR3 protein having an amino acid sequence in which at least one amino acid at a position corresponding to the above-mentioned position in SEQ ID NO: 1 has been mutated, or an FGFR3 gene encoding the amino acid sequence; more preferably, an FGFR3 protein having an amino acid sequence in which at least one amino acid selected from the group consisting of arginine at position 248 and glycine at position 380 in the amino acid sequence shown in SEQ ID NO: 1 has been mutated, or an FGFR3 gene encoding the amino acid sequence in the case of an FGFR3 protein whose wild-type amino acid sequence differs from that of SEQ ID NO: 1 has been mutated at least one amino acid at a position corresponding to the above-mentioned position in SEQ ID NO: 1; more preferably, an FGFR3 protein having an amino acid sequence in which glycine at position 380 in the amino acid sequence shown in SEQ ID NO: 1 has been mutated, or an FGFR3 gene encoding the amino acid sequence in the case of an FGFR3 whose wild-type amino acid sequence differs from that of SEQ ID NO: 1 has been mutatedHerein, when an FGFR3 protein is simply referred to as the Xth amino acid in SEQ ID NO: 1, unless otherwise specified, this refers to the Xth amino acid in the amino acid sequence shown in SEQ ID NO: 1, and the amino acid at the position corresponding to Xth in SEQ ID NO: 1 in the case of an FGFR3 protein whose wild-type amino acid sequence differs from SEQ ID NO: 1. Whether an amino acid in an FGFR3 protein whose wild-type amino acid sequence differs from SEQ ID NO: 1 corresponds to which amino acid position in SEQ ID NO: 1 can be confirmed, for example, by BLAST Multiple Alignment.

[0031] As FGFR3 in which glycine at position 380 or the glycine at position corresponding to position 380 in SEQ ID NO: 1 has been mutated, a mutation to arginine is preferred. Herein, FGFR3 in which glycine at position 380 or the glycine at position corresponding to position 380 in SEQ ID NO: 1 has been mutated may be referred to as G380R. The same applies to R248C, N540K, and K650E, which will be described later. As FGFR3 in which arginine at position 248 or the arginine at position 248 in SEQ ID NO: 1 has been mutated, a mutation to cysteine ​​is preferred, R248C. As FGFR3 in which asparagine at position 540 or the asparagine at position 540 in SEQ ID NO: 1 has been mutated, a mutation to lysine is preferred, N540K. As FGFR3 in which lysine at position 650 or the lysine at position 650 in SEQ ID NO: 1 has been mutated, a mutation to glutamic acid is preferred, K650E.

[0032] The FGFR3 mutation is preferably an FGFR3 protein consisting of an amino acid sequence having at least one amino acid mutation selected from the group consisting of R248C, G380R, N540K, and K650E, or an FGFR3 gene encoding said amino acid sequence, more preferably an FGFR3 protein consisting of an amino acid sequence having at least one amino acid mutation selected from the group consisting of R248C, G380R, and K650E, or an FGFR3 gene encoding said amino acid sequence, more preferably an FGFR3 protein consisting of an amino acid sequence having at least one amino acid mutation selected from the group consisting of R248C and G380R, or an FGFR3 gene encoding said amino acid sequence, and more preferably an FGFR3 protein having a G380R mutation, or an FGFR3 gene encoding said amino acid sequence.

[0033] Furthermore, as described above, even if the position of a mutation in a certain FGFR3 isoform differs from the position of the amino acid shown in SEQ ID NO: 1 due to an amino acid deletion, insertion, or the like, it is understood to be the same as a mutation at a position corresponding to the amino acid position shown in SEQ ID NO: 1. Thus, for example, glycine at position 380 in FGFR3 shown in SEQ ID NO: 1 corresponds to glycine at position 382 in FGFR3 consisting of the amino acid sequence shown in NCBI Reference Sequence: NP_001156685 (SEQ ID NO: 2). Therefore, in the present invention, unless otherwise specified, for example, "G380R" encompasses not only the FGFR3 shown in SEQ ID NO: 1 in which glycine at position 380 has been mutated to arginine, but also the FGFR3 consisting of the amino acid sequence shown in NCBI Reference Sequence: NP_001156685 in which glycine at position 382 has been mutated to arginine. Note that the corresponding amino acid position of an amino acid in a certain FGFR3 isoform in SEQ ID NO: 1 can be confirmed, for example, by BLAST Multiple Alignment.

[0034] In the present invention, "chondrodysplasia" refers to a disease caused by a decrease in the function of growth cartilage, such as achondroplasia, hypochondroplasia, or thanatophoric dysplasia, and is preferably achondroplasia, hypochondroplasia, or thanatophoric dysplasia, and more preferably achondroplasia.

[0035] Furthermore, in the present invention, "chondrodysplasia with FGFR3 mutation" includes diseases caused by decreased function of growth cartilage due to a mutation in glycine at position 380 in SEQ ID NO: 1 or a glycine at a position corresponding to position 380 in SEQ ID NO: 1, asparagine at position 540 in SEQ ID NO: 1, arginine at position 248 in SEQ ID NO: 1 or an arginine at position 248 in SEQ ID NO: 1, or lysine at position 650 in SEQ ID NO: 1; Preferred examples include achondroplasia having an FGFR3 mutation in which glycine at position 380 in SEQ ID NO: 1 or glycine at a position corresponding to position 380 in SEQ ID NO: 1 is mutated to arginine, hypochondroplasia having an FGFR3 mutation in which asparagine at position 540 in SEQ ID NO: 1 or asparagine at a position corresponding to position 540 in SEQ ID NO: 1 is mutated to lysine, or thanatophoric dysplasia having an FGFR3 mutation in which arginine at position 248 in FGFR3 represented by SEQ ID NO: 1 or arginine at a position corresponding to position 248 in SEQ ID NO: 1 is mutated to cysteine, or thanatophoric dysplasia having an FGFR3 mutation in which lysine at position 650 in FGFR3 represented by SEQ ID NO: 1 or lysine at a position corresponding to position 650 in SEQ ID NO: 1 is mutated to glutamic acid; More preferred examples include achondroplasia having an FGFR3 mutation in which glycine at position 380 in FGFR3 represented by SEQ ID NO: 1 or glycine at a position corresponding to position 380 in SEQ ID NO: 1 is mutated to arginine, or thanatophoric dysplasia having an FGFR3 mutation in which arginine at position 248 in FGFR3 represented by SEQ ID NO: 1 or arginine at a position corresponding to position 248 in SEQ ID NO: 1 is mutated to cysteine, or thanatophoric dysplasia having an FGFR3 mutation in which lysine at position 650 in FGFR3 represented by SEQ ID NO: 1 or lysine at a position corresponding to position 650 in SEQ ID NO: 1 is mutated to glutamic acid; More preferred examples include achondroplasia with an FGFR3 mutation in which glycine at position 380 in FGFR3 represented by SEQ ID NO: 1 or glycine at a position corresponding to position 380 in SEQ ID NO: 1 is mutated to arginine, and thanatophoric dysplasia with an FGFR3 mutation in which arginine at position 248 in FGFR3 represented by SEQ ID NO: 1 or arginine at a position corresponding to position 248 in SEQ ID NO: 1 is mutated to cysteine; Even more preferred is achondroplasia with an FGFR3 mutation in which glycine at position 380 in FGFR3 shown in SEQ ID NO: 1 or glycine at the position corresponding to position 380 in SEQ ID NO: 1 is mutated to arginine. Herein, chondrodysplasia with an FGFR3 mutation may also be simply referred to as FGFR3-mutated chondrodysplasia.

[0036] In the present invention, FGFR3 mutations can be detected by methods well known to those skilled in the art. For example, methods for detecting mutations in the FGFR3 gene include commonly used methods such as Southern blotting, PCR, DNA microarray, and sequence analysis. Methods for detecting mutations in the FGFR3 protein include commonly used methods such as techniques using antibodies that specifically bind to FGFR3 mutations (ELISA, Western blotting, immunostaining, etc.) and mass spectrometry. Antibodies that specifically bind to FGFR3 mutations can be commercially available or can be prepared by commonly used methods.

[0037] In the present invention, the term "sample" encompasses not only biological samples (e.g., cells, tissues, organs, body fluids (blood, lymph, etc.), digestive fluids, and urine), but also nucleic acid extracts (genomic DNA extracts, mRNA extracts, cDNA preparations and cRNA preparations prepared from mRNA extracts, etc.) and protein extracts obtained from these biological samples. Furthermore, the sample may be one that has been subjected to formalin fixation, alcohol fixation, freezing, or paraffin embedding. The biological sample may be one collected from a living organism. The method for collecting the biological sample may be appropriately selected depending on the type of biological sample.

[0038] In the present invention, Compound 1 or a pharmaceutically acceptable salt thereof may be used as a therapeutic agent for chondrodysplasia, or Compound 1 or a pharmaceutically acceptable salt thereof may be used as a pharmaceutical composition in combination with a pharmaceutical carrier. Thus, in one embodiment, the present invention provides a pharmaceutical composition containing Compound 1 or a pharmaceutically acceptable salt thereof.

[0039] When compound 1 or a pharmaceutically acceptable salt thereof is contained as an active ingredient in a formulation, it may be optionally combined with a pharmaceutical carrier, and various administration forms may be adopted depending on the purpose of prevention or treatment. Examples of administration forms include oral preparations, injections, suppositories, ointments, patches, etc., with oral preparations being preferred. Oral preparations may be in the form of tablets, capsules, granules, powders, syrups, etc., but are not particularly limited thereto. Each of these administration forms can be produced by a manufacturing method known and commonly used by those skilled in the art. Depending on the administration form, appropriate carriers such as excipients, diluents, fillers, disintegrants, etc. may be optionally added to the formulation or pharmaceutical composition.

[0040] The amount of Compound 1 or a pharmaceutically acceptable salt thereof to be incorporated into each of the above-mentioned dosage unit forms varies depending on the symptoms of the patient to which it is to be administered or on the dosage form, but is generally desirably 0.05 to 1000 mg per dosage unit for oral preparations, 0.01 to 500 mg per dosage unit for injections, and 1 to 1000 mg per dosage unit for suppositories.

[0041] The daily dose of Compound 1 or a pharmaceutically acceptable salt thereof varies depending on the patient's symptoms, body weight, age, sex, etc. and cannot be determined in general, but is usually about 1 to 1000 mg of Compound 1 or a pharmaceutically acceptable salt thereof per day for an adult (body weight 60 kg), preferably about 10 to 500 mg per day, and more preferably about 10 to 300 mg per day.

[0042] When the daily dose of Compound 1 or a pharmaceutically acceptable salt thereof is administered every day, the dose is, for example, about 1 to 200 mg of Compound 1 or a pharmaceutically acceptable salt thereof per day, preferably 2 to 100 mg per day, more preferably 4 to 50 mg per day, and even more preferably 10 to 40 mg per day.

[0043] When the daily dose of Compound 1 or a pharmaceutically acceptable salt thereof is administered intermittently, the dose is, for example, about 2 to 1000 mg of Compound 1 or a pharmaceutically acceptable salt thereof per day, preferably 10 to 500 mg per day, more preferably 20 to 200 mg per day, and even more preferably 50 to 160 mg per day.

[0044] The administration schedule of Compound 1 or a pharmaceutically acceptable salt thereof may be daily administration or intermittent administration.

[0045] As used herein, "daily administration" refers to an administration schedule in which one cycle is administered for 21 consecutive days, and a drug holiday may be provided after each cycle.

[0046] As used herein, "intermittent administration" is not particularly limited as long as it satisfies the conditions of at least two times a week and an interval of at least one day between administrations (the number of days between one administration day and the next administration day).

[0047] For example, an administration schedule in which one cycle is one week, in which Compound 1 or a pharmaceutically acceptable salt thereof is administered two or more times every one to three days per cycle (the interval between one administration day and the next administration day is one to three days), and the cycle is repeated one or more times; an administration schedule in which one cycle is 14 days, in which Compound 1 or a pharmaceutically acceptable salt thereof is administered 4 to 7 times per cycle with an interval of 1 to 3 days between each administration day, and the cycle is repeated one or more times; an administration schedule in which one cycle is 14 days, in which Compound 1 or a pharmaceutically acceptable salt thereof is administered on days 1, 4, 8, and 11 of the 14 days in one cycle; an administration schedule in which one cycle is 14 days, in which Compound 1 or a pharmaceutically acceptable salt thereof is administered on days 1, 3, 5, 7, 9, 11, and 13 of the 14 days in one cycle; Examples of such a schedule include a 14-day administration cycle in which Compound 1 or a pharmaceutically acceptable salt thereof is administered on days 1, 3, 5, 8, 10, and 12 of the 14 days in one cycle. In the present invention, the phrase "X days apart between one administration day and the next administration day" means that if administration is performed on day n, the next administration day is day n+(1+X). For example, the phrase "one day apart between one administration day and the next administration day" means that if administration is performed on day 1, the next administration day is day 3.

[0048] The present invention also provides a method for treating chondrodysplasia, comprising administering an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof to a patient with chondrodysplasia. Compound 1 or a pharmaceutically acceptable salt thereof, and the method of administration thereof, are as described above. Patients include humans and non-human mammals. Non-human mammals include, for example, monkeys, dogs, cats, rabbits, mice, rats, and guinea pigs. As described above, chondrodysplasia also includes FGFR3-mutated chondrodysplasia.

[0049] Therefore, in one embodiment, the present invention also provides a method for treating FGFR3 mutant chondrodysplasia, comprising the following steps (1) and (2): (1) detecting a mutation in an FGFR3 protein or an FGFR3 gene from a patient-derived sample; (2) A step of administering an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof to a patient in whom a mutation in an FGFR3 protein or an FGFR3 gene has been detected in the above step (1).

[0050] In one embodiment, the present invention also provides the following method: Administering an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof to a patient having a mutation in an FGFR3 protein or an FGFR3 gene; A method for treating FGFR3 mutant chondrodysplasia, comprising: A mutation in an FGFR3 protein or an FGFR3 gene is detected in a sample derived from the patient. method.

[0051] In the above-mentioned treatment method, it is predicted that chemotherapy involving the administration of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof will show a sufficient therapeutic effect in patients in whom a mutation in the FGFR3 protein or FGFR3 gene has been detected. Here, the "therapeutic effect" can be evaluated by bone lengthening effect, etc. Furthermore, the therapeutic effect can be estimated based on the level of FGFR3 function inhibitory activity (e.g., inhibitory activity using FGFR3 phosphorylation as an indicator). [Example]

[0052] The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto. Although the present invention has been fully explained with reference to examples, it is understood that various changes and modifications may be made by those skilled in the art. Therefore, as long as such changes and modifications do not deviate from the scope of the present invention, they are included in the present invention.

[0053] Example 1: Evaluation of the inhibitory activity of Compound 1 against FGFR3 mutants in vitro

[0054] 1-1 Construction of FGFR3 mutant expression vector The FGFR3 vector used was the FGFR3 (NM_000142) Human Tagged ORF Clone (FGFR3 wild-type (WT) expression vector) purchased from ORIGENE, and expression vectors for each mutant (G380R, N540K, and K650E) were constructed using this vector as a template.

[0055] 1-2 Measurement of FGFR3 inhibitory activity using FGFR3 phosphorylation as an indicator Human embryonic kidney cells HEK293T were cultured in DMEM medium containing 10% fetal bovine serum, and the cells were harvested by a conventional method and suspended in DMEM medium containing 10% fetal bovine serum. The above-described FGFR3 wild-type or mutant expression vectors were introduced into the cells by lipotransfection using Lipofectamine 3000 Reagent (ThermoFisher Scientific). The cells were then plated at 1.5 × 10 cells per well in a 96-well plate. 4 The cells were seeded at 100 μL.

[0056] As drug solutions, a vehicle (DMSO) group and various dilution series (a dilution series of 9 concentrations from 1000, 300, 100, 30, 10, 3, 1, and 0.3 nM, with a maximum final concentration of 3000 nM) of Compound 1 were prepared. After incubating the seeded cells at 37°C and 5% CO2 for 24 hours, 11 μL of medium containing the drug solution was added, and the cells were further incubated for 1 hour.

[0057] Functional inhibition of FGFR3 autophosphorylation was measured and evaluated using the Human Phospho-FGF R3 DuoSet IC ELISA (R&D SYSTEMS). Specifically, cells were lysed using the cell lysis solution provided with the kit, supplemented with a protease inhibitor (Roche) and a phosphatase inhibitor (Roche). The experiment was performed according to the kit's protocol, and colorimetric quantification was performed on each well using a plate reader (SpectraMAX384, Molecular Devices). The relative FGFR3 phosphorylation rate in the drug-treated wells was calculated as a ratio, with the control group set at 100%, according to the following formula. Experiments were performed in duplicate (two wells per treatment group), and the average of the data from each of the two wells was used for analysis.

[0058] Relative FGFR3 phosphorylation rate (%) = (signal amount in drug-added wells) / (signal level of control group) x 100

[0059] The IC50 value (50% inhibitory concentration) was calculated as the concentration that achieved 50% inhibition compared to the control group.

[0060] In 293T cell lines expressing FGFR3 wild-type (WT) or mutants (G380R, N540K, or K650E), Compound 1 exhibited the following inhibitory activity (Table 1).

[0061] [Table 1]

[0062] Example 2: Bone lengthening effect of Compound 1 in achondroplasia model mice

[0063] FGFR3ACH mice (Naski, MC et al. Development 1998, 125(24):4977-88; hereafter simply referred to as ACH mice) were used. FVB ACH mice were artificially inseminated to produce a large number of F1 hybrid mice. Genomic DNA was extracted and genotyped by PCR. Compound 1 was dissolved in 0.5% HPMC to prepare solutions of various concentrations. Compound 1 was administered at a dose of 0.1 mg / kg, 1 mg / kg, or 3 mg / kg at 10 mL / kg, depending on the individual's body weight on the day of administration. Mice were divided into a compound 1-treated group and a control group (vehicle administered with 0.5% HPMC) (WT and vehicle-treated groups: n = 5, compound 1-treated group: n = 6). From day 21 to day 42, the mice were intraperitoneally injected once daily, 5 days a week (5 days on, 2 days off). Mice were euthanized on day 43 of age, and their body weights and bone lengths (femur, tibia, and ulna) were measured by X-ray. X-rays were taken using a Faxitron X-ray DX-50 (Acrobio Co., Ltd.), and measurements were performed using ImageJ. A significant difference test was performed using Dunnett's multiple comparisons test. In Figures 1 to 5, * indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001.

[0064] As shown in Figures 1 to 5, at the time of measurement (43 days old), the Compound 1 administration group showed a concentration-dependent bone lengthening effect compared to the vehicle administration group. Next, femurs were isolated from the mice after administration, and the cartilage growth plates were stained with Safranin O and their lengths were measured. The results are shown in Figure 4. The average width of the growth plates in the ACH mice was 148.3 mm, and in the group of ACH mice administered Compound 1, it was 206.4 mm, confirming that they were longer than the vehicle-administered group.

[0065] Example 3: Bone lengthening effect of Compound 1 in achondroplasia model mice

[0066] The dose of Compound 1 was varied (male mice: 1 mg / kg, 3 mg / kg, or 10 mg / kg; female mice: 1 mg / kg, 3 mg / kg, or 6 mg / kg) in the same manner as in Example 2, and the bone lengthening effect was evaluated using both male and female mice (n = 10). A significant difference test was performed using Dunnett's multiple comparisons test, and in Figures 6 to 11, * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001.

[0067] As shown in FIGS. 6 to 11, at the time of measurement (43 days old), the Compound 1 administration group showed a concentration-dependent bone lengthening effect compared to the vehicle administration group.

[0068] Example 4: Drug efficacy evaluation in disease iPS cell models

[0069] We established iPS cell lines from skin fibroblasts of patients with thanatophoric dysplasia type I (TD1, R248C) and achondroplasia (ACH, G380A) and from healthy individuals, and induced their differentiation into chondrocytes. While cartilage tissue was formed from healthy iPS cells, tissues induced from TD1-iPS cells and ACH-iPS cells showed reduced cartilage components (Yamashita et al., Nature, 2014, 513(7519):507-11).

[0070] In this differentiation induction system, 1 nM of compound 1 was added every time the medium was changed (medium change was once every 2-7 days) starting from day 3 after the start of differentiation induction, and analysis was performed 10 weeks after differentiation induction. Rosuvastatin was used as a positive control. Evaluation items were tissue section staining (Safranin staining) and mRNA expression of COL2A1 and Aggrecan (ACAN). Significance tests were performed using an unpaired test, and * in Figure 13 indicates p<0.05.

[0071] As shown in FIG. 12, the addition of Compound 1 resulted in a positive staining image with safranin, which stains glycosaminoglycan, a component of the cartilage extracellular matrix. Furthermore, as shown in FIG. 13, the expression of COL2A1 and ACAN mRNA was increased in cells to which Compound 1 had been added, compared to cells to which Compound 1 had not been added.

Claims

1. A pharmaceutical composition for treating chondrodysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof.

2. A therapeutic agent for chondrodysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof.

3. 3. The pharmaceutical composition according to claim 1 or the therapeutic agent according to claim 2, wherein the chondrogenic dysplasia is achondroplasia, hypochondroplasia, or thanatophoric dysplasia.

4. The pharmaceutical composition according to claim 1 or the therapeutic agent according to claim 2, wherein the chondrodysplasia is achondroplasia.

5. The pharmaceutical composition according to claim 1 or the therapeutic agent according to claim 2, wherein the chondrodysplasia is chondrodysplasia with an FGFR3 mutation.

6. The pharmaceutical composition or therapeutic agent according to claim 5, wherein the FGFR3 mutation is a mutation at arginine at position 248, glycine at position 380, asparagine at position 540, or lysine at position 650 of FGFR3.

7. The pharmaceutical composition or therapeutic agent according to claim 5, wherein the chondrodysplasia with an FGFR3 mutation is achondroplasia with an FGFR3 mutation.

8. The pharmaceutical composition or therapeutic agent according to claim 7, wherein the achondroplasia is achondroplasia with an FGFR3 mutation in which glycine at position 380 of FGFR3 is mutated to arginine.

9. The pharmaceutical composition or therapeutic agent according to claim 5, wherein the chondrodysplasia with an FGFR3 mutation is hypochondroplasia with an FGFR3 mutation.

10. The pharmaceutical composition or therapeutic agent according to claim 9, wherein the hypochondroplasia is hypochondroplasia with an FGFR3 mutation in which asparagine at position 540 of FGFR3 is mutated to lysine.

11. The pharmaceutical composition or therapeutic agent according to claim 5, wherein the chondrodysplasia with an FGFR3 mutation is thanatophoric skeletal dysplasia with an FGFR3 mutation.

12. The pharmaceutical composition or therapeutic agent according to claim 11, wherein the thanatophoric dysplasia is thanatophoric dysplasia having an FGFR3 mutation in which arginine at position 248 of FGFR3 is mutated to cysteine, or an FGFR3 mutation in which lysine at position 650 is mutated to glutamic acid.

Images